EGFR and neoplasm: GC1118, a novel fully human anti-EGFR IgG1 antibody, exhibited potent inhibitory effects on EGFR signaling, enhanced antibody-mediated cytotoxicity, and significantly inhibited tumor growth in a CRC patient-derived xenograft (PDX) model [44].